Skip to main content
    I

    Innate Pharma (IPHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.48
    +0.05 (+3.50%)

    Market Cap: $164.20M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(13/17)
    Avg Surprise
    +8.97%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.14-8.7%
    60d ago$-0.07-114.3%
    30d ago$-0.07-114.3%
    7d ago$-0.07-114.3%
    Current$-0.15
    Revenue Consensus
    $2M
    Range$2M - $2M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.22
    Range$-0.12 - $0.56
    2 analysts
    Revenue Consensus
    $31M
    Range$-4572000 - $72M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.22---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Sep 17
    		$N/A$-0.09N/ABeat-
    Mar 26
    Reported May 13
    		$0.00N/A+100.00%Beat+100.0%
    Dec 25
    Reported Dec 31
    		$N/A$-0.14N/ABeat-
    Sep 25
    Reported Nov 13
    		$-0.14$-0.14-1.57%Miss-
    Jun 25
    Reported Sep 17
    		$-0.30N/AN/ABeat+3.2%
    Mar 25
    Reported May 12
    		$-0.30$-0.40+25.00%Beat-
    Dec 24
    Reported Mar 27
    		$-0.30$-0.40+25.00%Beat-160.4%
    Sep 24
    Reported Nov 13
    		$0.00$0.00N/ABeat-
    Jun 24
    Reported Sep 12
    		$-0.31$-0.38+19.42%Beat-1593.7%
    Mar 24
    Reported May 14
    		$0.00$0.00N/ABeat-
    Dec 23
    Reported Mar 21
    		$-0.12N/A+71.90%Beat-
    Sep 23
    Reported Nov 14
    		$0.00$0.00N/ABeat-
    Jun 23
    Reported Sep 14
    		$0.02N/A+114.64%Beat-
    Mar 23
    Reported May 10
    		$0.00$0.00N/ABeat+100.0%
    Dec 22
    Reported Mar 23
    		$0.00N/A+100.00%Beat+100.0%
    Sep 22
    Reported Nov 14
    		$0.00$0.00N/ABeat-
    Jun 22
    Reported Sep 15
    		$0.00N/A+100.00%Beat-
    Mar 22
    Reported Apr 3
    		$-0.16$-0.17+5.88%Beat+11.1%
    Dec 21
    Reported Mar 24
    		$-0.66$0.00N/AMiss-275.0%
    Sep 21
    Reported Nov 16
    		$0.00$0.00N/ABeat+100.0%
    Jun 21
    Reported Sep 15
    		$0.00$0.00N/ABeat+100.0%
    Mar 21
    Reported Apr 26
    		$-0.18$0.05-460.00%Miss-144.6%
    Dec 20
    Reported Mar 18
    		$-0.18$-0.09-95.56%Miss+2.2%
    Sep 20
    Reported Nov 17
    		$-0.09$-0.09+0.00%Beat-312.4%
    Jun 20
    Reported Sep 8
    		$-0.08$-0.08-3.38%Miss+6.4%
    Mar 20
    Reported May 12
    		$-0.07$0.00N/AMiss-
    Dec 19
    Reported Mar 10
    		$-0.18$-0.18+0.00%Beat-327.6%
    Sep 19
    Reported Nov 13
    		$0.04N/A+149.44%Beat+114.6%
    Jun 19
    Reported Sep 13
    		$-0.09$-0.09+1.78%Beat+83.5%
    Mar 19
    Reported May 15
    		$0.00$0.00N/ABeat-
    Sep 18
    Reported Nov 15
    		$0.08$0.00N/ABeat+116.0%
    Jun 18
    Reported Jun 30
    		$-0.30N/AN/ABeat-
    Dec 17
    Reported Dec 31
    		$-0.54N/AN/ABeat-278.9%
    Sep 17
    Reported Nov 15
    		$0.00$0.00N/ABeat-
    Jun 17
    Reported Jun 30
    		$-0.49N/AN/ABeat-
    Mar 17
    Reported May 15
    		$0.00$0.00N/ABeat-
    Dec 16
    Reported Dec 31
    		$0.30N/AN/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF-1.16xFCF Yield-85.95%
    Profitability
    Profit Margin0.00%Operating Margin-335.70%
    ROE-271.40%ROIC501.86%
    Financial Health
    Debt/Equity-0.50xInterest Coverage-17.84x
    Current Ratio0.60xQuick Ratio0.60x
    Trading Statistics
    Beta1.19Avg Volume61.25K
    52-Week High$2.7152-Week Low$1.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.52
    SMA 20$1.62
    SMA 50$1.91
    SMA 200$1.73
    EMA 10$1.53
    EMA 20$1.62
    EMA 50$1.77
    EMA 200$1.80

    MACD

    Line: -0.12Signal: -0.12Hist: -0.00

    ADX

    ADX: 8.6+DI: 26.3-DI: 20.8

    Aroon & PSAR

    Aroon Up16.0
    Aroon Down96.0
    PSAR$1.65

    Bollinger Bands

    Upper Band$1.89
    Lower Band$1.35
    %B Position3307%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    36.6

    Momentum Oscillators

    Stoch %K8.3
    Stoch %D10.1
    Williams %R-83.8
    ROC (10d)-6.9%
    Momentum-0.11
    CCI (20d)-79.6
    MFI (14d)38.2

    Volatility Measures

    ATR (14d)$0.12(7.9%)
    StdDev (20d)0.13
    Hist Vol59.1%(High)

    Volume Flow

    VWAP$1.51
    OBV19.3M
    AD Line1.8M
    CMF (20d)-0.162

    Volume Metrics

    Avg Vol (20d)47.1K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.66

    Pivot Points

    R3$1.50
    R2$1.48
    R1$1.46
    Pivot Point$1.44
    S1$1.41
    S2$1.39
    S3$1.37

    Advanced Oscillators

    TSI-31.30
    Ultimate Osc33.9
    KST-229.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$3.16M$-2,073,000$-2,073,000$4.86M$276,000$276,000$12.35M$16.56M$21.44M$10.72M$35.34M$20.10M
    Cost of RevenueN/AN/AN/A$20.52M$-29,076,000$-29,076,000$29.08M$24.57M$24.57M$12.28M$15.73M$15.73M
    Gross ProfitN/A$18.45M$18.45M$-15,660,000$29.35M$29.35M$-16,731,000$-3,126,000$-3,126,000$-1,563,000$19.62M$4.37M
    Operating Expenses$24.39M$46.45M$46.45M$9.77M$54.61M$54.61M$9.58M$9.14M$8.06M$4.03M$36.95M$3.83M
    R&D$0$22.93M$22.93M$20.52M$22.90M$22.90M$29.08M$24.57M$24.57M$12.28M$28.41M$15.73M
    SG&A$0$1.39M$1.39M$9.61M$2.52M$2.35M$9.42M$8.97M$8.97M$4.49M$8.47M$4.50M
    Operating Income$-21,849,197$-27,998,000$-27,998,000$-25,427,000$-25,262,000$-25,262,000$-26,313,000$-7,416,000$-12,270,000$-6,135,000$-5,253,000$-199,500
    Interest Income$0$0$0$0$0$101,000$0$0$0$0$0$0
    Interest Expense$172,287$2.87M$2.87M$250,110$34,000$34,000$600,000$3.02M$3.02M$0$324,000$94,000
    Income Before Tax$-22,469,436$-27,833,000$-27,833,000$-21,344,000$-24,707,000$-24,707,000$-24,764,000$-4,434,000$-9,288,000$-4,644,000$-3,136,000$859,000
    Income Tax Expense$-2,582,297$-2,993,675$-2,993,675$0$0$0$0$-9,750,000$-9,750,000$0$-4,854,000$-3,765,000
    Net Income$-19,887,138$-27,626,979$-27,626,979$-21,344,000$-24,707,000$-24,707,000$-24,764,000$-9,288,000$-9,288,000$-4,644,000$1.72M$859,000
    EBITDA$-21,238,197$-30,705,025$-30,705,025$-24,724,036$-21,760,831$-21,348,000$-25,160,426$-10,784,521$-10,396,000$-5,198,000$832,000$1.41M
    EBIT$-21,849,197$-31,377,013$-31,377,013$-25,427,000$-22,592,000$-22,592,000$-26,313,000$-12,270,000$-12,270,000$-6,135,000$-2,813,000$-199,500
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IPHA

    News

    Diluted earnings per share (diluted EPS) of Innate Pharma SA Sponsored ADR – HAM:IDDA

    This article provides a headline about the diluted earnings per share (diluted EPS) of Innate Pharma SA Sponsored ADR...

    TradingView•10/11/26•Neutral

    Full Year 2025 Innate Pharma SA Earnings Call Transcript

    This article provides the transcript of Innate Pharma SA's Full Year 2025 Earnings Call, held on March 26, 2026. Key points include FDA clearance for the Telemax 3 phase 3 trial for lacutamab...

    GuruFocus•10/8/26•Neutral

    Innate Pharma S.A. (IPH.PA) Stock Price, News, Quote & History

    This article provides a detailed financial overview of Innate Pharma S.A. (IPH.PA), including its current stock price, performance metrics, and key financial data. It also outlines the company's biotechnology focus...

    Yahoo! Finance Canada•10/7/26•Neutral

    Innate Pharma S.A. (IPHP.XC) balance sheet

    This article provides the balance sheet for Innate Pharma S.A. (IPHP.XC) as of April 16, 2026. It includes annual financial data from 2022 to 2025, detailing total assets, liabilities, equity...

    Yahoo Finance UK•10/6/26•Bearish

    Return on invested capital % of Innate Pharma SA Class A – HAN:IDD

    The article presents the "Return on invested capital %" for Innate Pharma SA Class A (HAN:IDD) as displayed on TradingView. It indicates that the market was closed with no trades recorded for this specific financial...

    TradingView•9/29/26•Neutral

    IPHA Valuation and Fair Value

    P/FCF
    -1.2x
    P/B
    -3.0x
    See GNG's fair value

    IPHA Profitability: Margins, ROIC and FCF

    Operating margin
    -335.7%
    Net margin
    0.0%
    ROIC
    501.9%
    ROE
    -271.4%
    FCF margin
    -2275.3%
    FCF yield
    -86.0%

    IPHA Competitors

    CompanyTicker
    Coherus BioSciences IncCHRS
    PepGen LtdPEPG
    Precision BioSciences IncDTIL
    Inogen IncINGN
    Whitehawk Therapeutics, Inc.WHWK
    EDAP TMS SAEDAP
    Oramed Pharmaceuticals IncORMP
    Journey Medical CorpDERM

    Sector: Healthcare

    IPHA Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IPHA Bull Case vs Bear Case

    Bull case

    • IPHA earns a 501.9% return on invested capital.
    • IPHA grew quarterly revenue 16.5% year over year.

    IPHA Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    40.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About IPHA

    Does IPHA pay dividends?

    Innate Pharma (IPHA) does not currently pay a regular dividend.

    What is IPHA's market cap?

    Innate Pharma (IPHA) has a market capitalization of $164.20M with a current stock price of $1.48.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In